Biogen, Inc. (BIIB)
$265.12
0.35 (0.13%)
BIIB Stock Quote Delayed 30 Minutes
Previous Close
$265.12
Market Cap
55.94B
PE Ratio
18.94
EPS
14
Volume (Avg. Vol.)
943,000
Day's Range
264.12 - 267.98
52-Week Range
215.77 - 374.99
Dividend & Yield
N/A (N/A)
BIIB Stock Predictions, Articles, and Biogen, Inc. News
Biogen News: BIIB Stock Battered 7% by MS Drug Patent Ruling
Biogen (BIIB) news for Thursday concerning a lost court ruling surrounding its multiple sclerosis drug has BIIB stock taking a beating.
As Biogen Stock Struggles, Look Elsewhere for Biotech Exposure
Biogen has solid and consistent revenue, profit and cash flow. But Biogen stock has a low valuation because it has no growth.
Nothing Will Stop Biogen Stock From Moving Higher
The Alzheimer's-drug delay disappointed Biogen stock owners, but the long-term outlook for the company remains solid.
3 Big Stock Charts for Thursday: Snap, Biogen, and L Brands
Thursday's big stock charts feature names that released noteworthy earnings data.
3 Big Stock Charts for Thursday: Goldman Sachs, FedEx, and Biogen
Thursday's big stock charts feature names that outperformed during a major market surge.
3 Big Stock Charts for Tuesday: Biogen, Activision Blizzard, and Plug Power
Tuesday's big stock charts feature stocks holding support whose businesses could, and maybe should, hold up in the near term.
Stock Market Today: New Record Highs; An $8 Trillion Opportunity
Ford and Disney sank on earnings, while oil demand could shrivel up in China. Here's what happened in the stock market today.
3 Big Stock Charts for Wednesday: Biogen, Cooper Companies, and Maxim
Wednesday's big stock charts highlight 3 stocks looking to break through resistance in a market that looks a bit shaky at the moment.
5 Top Stock Trades for Friday: RH, DG, KR, BIIB
RH, Dollar General, Kroger, Biogen and Signet Jewelers were our top stock trades for Friday. Let's look at the charts.
The Good, Bad, and Ugly for Biogen Stock
With news that Biogen’s Alzheimer’s drug was allowed to reapply for possible FDA approval, Biogen stock skyrocketed. However, investors will want to carefully consider all angles before jumping onboard.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
B
